A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

Clinical trial NCT00524368 · COMPLETED

Trial details

NCT number: NCT00524368
Sponsor: Tibotec Pharmaceuticals, Ireland
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Human Immunodeficiency Virus - Type 1

Start date: 2007-10-01
Primary completion: 2009-08-01
Enrollment: 590

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.